| NCT04120961 | Nanjing First Hospital, Nanjing Medical University | Coronary Heart Disease | 2019-09-20 | NA |
| NCT01651780 | The Medicines Company | Severe Aortic Stenosis|Transcatheter Aortic Valve Replacement|Aortic Valve Replacement | 2012-10 | PHASE3 |
| NCT01465503 | Clinica Mediterranea | Bleeding | 2008-01 | PHASE3 |
| NCT00373451 | Deutsches Herzzentrum Muenchen | Myocardial Infarction|Coronary Disease | 2006-07 | PHASE4 |
| NCT01848899 | NYU Langone Health|Guerbet | Coronary Artery Disease | 2013-02 | PHASE4 |
| NCT06080074 | Stanford University|Boston Children´s Hospital|Duke University|FDA Office of Orphan Products Development | Heart Failure|Cardiogenic Shock|Congenital Heart Disease|Cardiomyopathies | 2025-04-15 | PHASE2 |
| NCT05959252 | Sydney Local Health District | Extracorporeal Membrane Oxygenation Complication | 2024-05-01 | PHASE2 |
| NCT00043277 | The Medicines Company | Thrombosis | 2002-08 | PHASE2 |
| NCT04046029 | The First Affiliated Hospital of Dalian Medical University|Beijing Friendship Hospital | Acute Coronary Syndrome|Percutaneous Coronary Intervention|Aging|Anticoagulants and Bleeding Disorders | 2019-07-08 | PHASE4 |
| NCT01913483 | The Medicines Company | Peripheral Endovascular Interventions|Bleeding | 2013-09-24 | PHASE3 |
| NCT00073593 | The Medicines Company | Cardiac Surgery|Coronary Artery Bypass Surgery | 2003-08 | PHASE3 |
| NCT04475835 | First Affiliated Hospital Xi´an Jiaotong University | STEMI With Multivessel Coronary Disease | 2021-01-12 | NA |
| NCT00448461 | Careggi Hospital | Coronary Artery Disease | 2007-03 | PHASE4 |
| NCT02311231 | Uppsala University|Lund University | ST-segment Elevation Myocardial Infarction|Non ST-segment Elevation Myocardial Infarction | 2014-06 | PHASE4 |
| NCT05334654 | University Magna Graecia | Acute Respiratory Failure|SARS CoV 2 Infection|Anticoagulants | 2022-04-20 | NA |
| NCT00503126 | The Medicines Company | Cardiology | 2007-08 | PHASE2 |
| NCT04185077 | Second Xiangya Hospital of Central South University | STEMI - ST Elevation Myocardial Infarction | 2019-11-30 | PHASE4 |
| NCT01464671 | Stony Brook University | Coronary Artery Disease | 2009-07 | PHASE4 |
| NCT00079508 | The Medicines Company | Cardiovascular Disease|Coronary Artery Bypass Surgery | 2004-04 | PHASE3 |
| NCT00043940 | The Medicines Company | Heparin-Induced Thrombocytopenia|Thrombosis | 1999-04 | PHASE3 |
| NCT00370045 | LifeBridge Health | Coronary Artery Disease | 2006-03 | PHASE4 |
| NCT03965208 | Legacy Health System|Pacific University | Extracorporeal Membrane Oxygenation Complication|Anticoagulants | 2019-05-23 | PHASE4 |
| NCT00759083 | The Medicines Company | Heparin-Induced Thrombocytopenia|Heparin-induced Thrombocytopenia and Thrombosis Syndrome | 2008-09 | PHASE4 |
| NCT06861374 | First Affiliated Hospital Xi´an Jiaotong University | ST-segment Elevation Myocardial Infarction (STEMI) | 2025-05 | NA |
| NCT02787317 | Chinese PLA General Hospital | Coronary Disease | 2016-05 | PHASE4 |
| NCT00433966 | Cardiovascular Research Foundation, New York|Boston Scientific Corporation|The Medicines Company | Myocardial Infarction | 2005-03 | PHASE3 |
| NCT03537586 | NYU Langone Health | Coronary Microvascular Disease|Ischemic Heart Disease|Myocardial Ischemia | 2018-06-29 | NA |
| NCT03882775 | The First Affiliated Hospital of Dalian Medical University|Beijing Friendship Hospital | STEMI|Percutaneous Coronary Intervention|Aged | 2019-01-16 | PHASE4 |
| NCT01157455 | CCRF Consulting Co., Ltd. | Coronary Artery Diseases | 2010-05 | PHASE4 |
| NCT05984537 | Peking University First Hospital | Coronary Microvascular Dysfunction | 2023-07-01 | PHASE4 |
| NCT01084993 | Laval University | Coronary Artery Disease | 2010-03 | PHASE4 |
| NCT00093158 | The Medicines Company | Unstable Angina|Myocardial Infarction|Acute Disease | 2003-08 | PHASE3 |
| NCT03707418 | Johns Hopkins University | Extracorporeal Membrane Oxygenation Complication | 2021-04 | PHASE1 |
| NCT01433627 | Italian Society of Invasive Cardiology|Eustrategy | Acute Coronary Syndromes|STEMI|NSTEMI | 2011-10 | PHASE3 |
| NCT02448550 | Kaiser Permanente | Percutaneous Coronary Intervention | 2015-05 | PHASE3 |
| NCT00317343 | Nycomed | Coronary Disease | 2006-03 | |
| NCT01696110 | Shenyang Northern Hospital | Acute Myocardial Infarction|Percutaneous Coronary Intervention | 2012-08 | PHASE4 |
| NCT03664180 | Beijing Anzhen Hospital|Chinese Academy of Medical Sciences, Fuwai Hospital|Groupe Hospitalier Pitie-Salpetriere | STEMI - ST Elevation Myocardial Infarction | 2019-01-11 | PHASE4 |
| NCT03588611 | Han Yaling, MD | Acute Coronary Syndrome | 2019-10-01 | PHASE4 |
| NCT00616460 | HaEmek Medical Center, Israel | Hematologic Diseases | 2008-02 | PHASE3 |
| NCT04195997 | Shanghai Zhongshan Hospital | Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk | 2020-02-01 | PHASE4 |
| NCT06275555 | Xiaotong Hou | Extracorporeal Membrane Oxygenation Complication | 2024-06-03 | NA |
| NCT01555658 | University of Roma La Sapienza | Coronary Artery Disease | 2012-04 | PHASE3 |
| NCT00464087 | Medstar Health Research Institute|GlaxoSmithKline | Acute Coronary Syndromes | 2007-06 | PHASE3 |
| NCT01848106 | Regado Biosciences, Inc.|The Cleveland Clinic|Duke Clinical Research Institute|Canadian VIGOUR Centre|Icahn School of Medicine at Mount Sinai|Parexel | Coronary Artery Disease | 2013-09 | PHASE3 |
| NCT04445935 | Hamad Medical Corporation | Anticoagulation in COVID-19 ARDS | 2020-06-28 | PHASE4 |
| NCT01642238 | Juan J Badimon|AstraZeneca | Acute Coronary Syndrome | 2012-07 | PHASE4 |
| NCT02565147 | The Medicines Company | Acute Myocardial Infarction | 2014-12-19 | PHASE3 |
| NCT00669149 | Centre Hospitalier de PAU | Coronary Artery Disease | 2008-06 | PHASE4 |
| NCT01519518 | Liverpool Heart and Chest Hospital NHS Foundation Trust | Acute ST Elevation Myocardial Infarction | 2012-02 | PHASE4 |
| NCT00812370 | Children´s Hospital Los Angeles|Baylor College of Medicine|Children´s Hospital Colorado|Children´s Hospital of Philadelphia|Nationwide Children´s Hospital|University of Texas Southwestern Medical Center | Deep Venous Thrombosis | 2008-09 | PHASE1 |
| NCT00079586 | The Medicines Company | Cardiovascular Disease|Coronary Artery Bypass Surgery | 2004-04 | PHASE3 |
| NCT00262054 | Deutsches Herzzentrum Muenchen | Coronary Disease|Angina Pectoris | 2005-11 | PHASE4 |
| NCT00976092 | Deutsches Herzzentrum Muenchen | Myocardial Infarction | 2009-09 | PHASE4 |
| NCT04532333 | Changhai Hospital|The First Affiliated Hospital of Zhengzhou University|Zhejiang University|Wuhan University|Qilu Hospital of Shandong University|The First People´s Hospital of Changzhou | Subarachnoid Hemorrhage, Aneurysmal | 2020-08 | PHASE3 |
| NCT00093184 | The Medicines Company | Myocardial Infarction | 2004-04 | PHASE3 |
| NCT03567408 | Qian Gong | Coronary Heart Disease | 2018-09-15 | PHASE2 |
| NCT03318393 | University of Texas Southwestern Medical Center | Extracorporeal Membrane Oxygenation Complication|Pediatric ALL|Anticoagulants | 2018-03-25 | PHASE4 |
| NCT03532399 | Boston Children´s Hospital | Drug Effect | 2018-07-12 | |
| NCT01087723 | The Medicines Company | Acute Coronary Syndrome | 2010-03 | PHASE3 |
| NCT02384070 | Odessa Heart Institute | Coronary Artery Disease | 2009-01 | NA |
| NCT02897037 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Acute Myocardial Infarction | 2016-11 | PHASE3 |